Enteric Disease Testing Market Size & Growth Forecast 2027–2036, By Segments (Disease), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Enteric Disease Testing Market size was estimated at USD 4.2 billion in 2026 and is projected to grow at a 2.95% CAGR from 2027 to 2036, attaining USD 5.62 billion by 2036. The industry revenue for 2027 is assessed at USD 4.3 billion.
Get more details on this report
Request Free Sample ReportEnteric Disease Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 29.27% share in 2026, supported by advanced laboratory networks, high testing volumes, established molecular diagnostics, and routine hospital-based testing for gastrointestinal infections.
- Asia Pacific is forecast to grow at a 3.08% CAGR as diagnostic access improves, laboratory capacity expands, and healthcare providers increasingly adopt confirmed testing over symptom-based treatment approaches.
Segment Momentum
- Bacterial disease testing captured 62.48% of the market in 2026, supported by consistently high testing volumes, established diagnostic workflows, and the need for rapid identification to guide treatment and infection control.
- Parasitic testing is expanding rapidly because it addresses diagnostic needs for persistent or unexplained gastrointestinal symptoms when routine bacterial testing does not provide conclusive results.
Market Expansion Drivers
- Rising prevalence of enteric infections and outbreak incidence increasing diagnostic demand globally.
- Expansion of molecular diagnostics and rapid PCR-based gastrointestinal panel testing adoption.
- Government-led screening programs and early diagnosis awareness initiatives improving testing penetration.
Leading Market Participants
- Major players in the enteric disease testing market include Abbott Laboratories (United States), Becton, Dickinson and Company (United States), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (United States), Cepheid, Inc. (United States), DiaSorin S.p.A. (Italy), Meridian Bioscience, Inc. (United States), Quest Diagnostics Incorporated (United States), Biomerica, Inc. (United States), Coris BioConcept SPRL (Belgium).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.2 billion
- 2027 Estimated Market Size: USD 4.3 billion.
- Projected Market Size: USD 5.62 billion by 2036
- Growth Forecast: 2.95% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Bacterial (Disease)
- Emerging Opportunity Segment: Parasitic (Disease)
Market Growth Drivers and Industry Trends
Rising prevalence of enteric infections and outbreak incidence increasing diagnostic demand globally
The enteric disease testing market is being driven by the rising prevalence of enteric infections and the occurrence of disease outbreaks, which increase the need for timely diagnostic assessment. Greater testing demand enables healthcare providers to identify gastrointestinal infections more efficiently and support appropriate clinical management when infectious conditions emerge.
Expansion of molecular diagnostics and rapid PCR-based gastrointestinal panel testing adoption
Expansion of molecular diagnostic technologies is accelerating the enteric disease testing market as healthcare providers adopt rapid PCR-based gastrointestinal panels for broader and faster pathogen identification. These testing approaches can streamline diagnostic workflows by enabling multiple gastrointestinal targets to be assessed through a more efficient testing process.
Government-led screening programs and early diagnosis awareness initiatives improving testing penetration
Government-led screening initiatives and growing awareness of early diagnosis are strengthening the enteric disease testing market by encouraging more systematic testing practices. Public health programs can improve access to diagnostic services, while greater awareness of timely detection encourages individuals and healthcare providers to pursue testing when enteric infections are suspected.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising incidence of enteric diseases in developing countries | 1.00% | Short term (≤ 2 yrs) | Asia Pacific, Latin America (spillover: North America) | High | Fast |
| Development of rapid diagnostic tests | 0.80% | Medium term (2–5 yrs) | Europe, Asia Pacific (spillover: North America) | Medium | Moderate |
| Adoption of preventive healthcare measures and vaccination | 0.50% | Long term (5+ yrs) | North America, Europe (spillover: Asia Pacific) | Medium | Slow |
| Rising prevalence of enteric infections and outbreak incidence increasing diagnostic demand globally | 2.30% | High | North America, Asia Pacific, Africa | High | Near Term |
| Expansion of molecular diagnostics and rapid PCR-based gastrointestinal panel testing adoption | 2.00% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Government-led screening programs and early diagnosis awareness initiatives improving testing penetration | 1.80% | High | Global | Medium | Near Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the enteric disease testing market with a 29.27% share in 2026, supported by advanced diagnostic infrastructure, established laboratory networks, and strong emphasis on infectious disease surveillance. Well-developed healthcare systems enable broad use of laboratory-based testing for identifying bacterial, viral, and parasitic gastrointestinal infections, while growing attention to rapid and accurate diagnosis supports continued demand for advanced testing methods. Public health preparedness, food safety monitoring, and established clinical laboratory capabilities further contribute to regional market strength. Increasing adoption of molecular and other high-sensitivity diagnostic approaches is also improving the ability of healthcare providers to detect enteric infections efficiently.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth in the enteric disease testing market, driven by expanding healthcare access, persistent infectious disease burdens, and increasing investment in diagnostic infrastructure. Rapid urbanization and improvements in sanitation and public health systems are increasing the need for effective disease surveillance and timely diagnosis. Growing laboratory capacity and wider availability of modern diagnostic technologies are enabling healthcare facilities to strengthen testing capabilities, particularly in developing healthcare markets. Greater awareness of foodborne and waterborne diseases, together with government efforts to improve infectious disease monitoring, is creating additional opportunities for enteric disease testing across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Quality StandardsGermany prioritizes highly standardized laboratory testing supported by rigorous quality assurance practices. Diagnostic providers in Germany continue adopting advanced molecular assays that improve pathogen detection accuracy while strengthening public health surveillance.
France 🇫🇷
Public Health DiagnosticsFrance strengthens enteric disease testing through coordinated laboratory networks supporting food safety and infectious disease monitoring. French healthcare providers increasingly implement molecular testing solutions that enable timely clinical intervention and surveillance activities.
Italy 🇮🇹
Hospital Testing ModernizationItaly continues modernizing microbiology laboratories by incorporating automated and molecular enteric disease testing platforms. Healthcare facilities across Italy emphasize faster diagnostic turnaround and improved detection capabilities for gastrointestinal infections.
Japan 🇯🇵
Infection Surveillance SupportJapan focuses on early detection of enteric pathogens through advanced laboratory diagnostics and coordinated surveillance programs. Healthcare institutions continue investing in sensitive testing technologies that improve outbreak management and clinical decision-making.
South Korea 🇰🇷
Rapid Testing IntegrationSouth Korea expands the use of rapid molecular diagnostics across hospitals and clinical laboratories to accelerate enteric disease detection. The country's focus on laboratory modernization supports efficient identification of infectious agents and improved patient management.
United States 🇺🇸
Multiplex Diagnostics FocusThe U.S. emphasizes rapid molecular and multiplex diagnostic platforms that improve identification of gastrointestinal pathogens. Clinical laboratories increasingly adopt automated workflows to support faster diagnosis, infection control, and appropriate treatment decisions.
Segment Leadership and Growth Trends
Enteric Disease Testing Market Share (%), by Disease, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDisease Segment Analysis: Bacterial (Largest Segment) vs Parasitic (Fastest-Growing Segment)
The bacterial segment accounted for 62.48% of the enteric disease testing market in 2026, reflecting the substantial diagnostic demand associated with bacterial infections affecting the gastrointestinal tract. Testing for bacterial pathogens is essential for identifying causative organisms and supporting appropriate clinical management, particularly where symptoms can overlap across different enteric conditions. Increasing emphasis on timely diagnosis, infection surveillance, and accurate pathogen identification continues to support the segment's strong position.
Parasitic diseases are expected to register the fastest growth as diagnostic programs increasingly emphasize the detection of intestinal parasites that can contribute to persistent gastrointestinal illness and broader public health concerns. Improvements in laboratory testing capabilities and greater awareness of water- and food-associated transmission are encouraging more comprehensive parasitic disease screening. Expanding diagnostic access and the need for accurate identification of parasitic infections are further supporting demand for specialized testing solutions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Disease | Bacterial, Viral, Parasitic | Bacterial | Parasitic |
Competitive Landscape and Market Positioning
Prominent players in the enteric disease testing market:
1. Abbott Laboratories (United States)
2. Becton Dickinson and Company (United States)
3. bioMérieux SA (France)
4. Bio-Rad Laboratories Inc. (United States)
5. Cepheid Inc. (United States)
6. DiaSorin S.p.A. (Italy)
7. Meridian Bioscience Inc. (United States)
8. Quest Diagnostics Incorporated (United States)
9. Biomerica Inc. (United States)
10. Coris BioConcept SPRL (Belgium)
The enteric disease testing market is expanding due to increased focus on rapid pathogen detection and laboratory automation. Advanced diagnostic techniques are improving sensitivity and reducing testing time. The enteric disease testing market is also seeing development of multiplex testing solutions for broader disease identification. Rising global health surveillance needs are accelerating adoption across healthcare settings.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Cepheid Inc. (United States) | |||||||
| DiaSorin S.p.A. (Italy) | |||||||
| Meridian Bioscience Inc. (United States) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Biomerica Inc. (United States) | |||||||
| Coris BioConcept SPRL (Belgium). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BIOMÉRIEUX | 2025 | BIOMÉRIEUX expanded digital laboratory integration technologies to improve connectivity and workflow efficiency in diagnostic laboratories. This enhancement strengthens its molecular diagnostics ecosystem and supports more integrated enteric disease testing operations. |
| DiaSorin S.p.A. | 2025 | DiaSorin S.p.A. developed high-sensitivity gastrointestinal diagnostic assays, enhancing detection performance in enteric disease testing. This advancement supports improved diagnostic accuracy and strengthens its molecular and immunodiagnostic product portfolio. |
| Gavi, UNICEF, WHO, FIND | Apr-24 | A coordinated global deployment of over 1.2 million cholera rapid diagnostic tests was initiated across multiple countries, including Malawi. Led by Gavi, UNICEF, WHO, FIND, and partners, the initiative enhances outbreak detection capacity and supports more effective cholera surveillance and vaccination planning. |
| BD | 2024 | BD introduced automated infectious disease diagnostic systems, improving laboratory workflow efficiency and supporting higher-throughput enteric disease testing. The initiative strengthens its competitive positioning in automated diagnostic platforms for clinical laboratories. |
| Cepheid | 2024 | Cepheid launched rapid multiplex enteric pathogen testing assays, expanding its molecular diagnostics portfolio for gastrointestinal infections. The development enhances rapid detection capabilities and supports improved clinical decision-making in enteric disease management. |
| Avacta | Jun-23 | Avacta acquired Coris Bioconcept as part of its strategy to transition into a pure-play biotech company. The acquisition consolidates its diagnostics portfolio and strengthens its focus on infectious disease testing capabilities within its remaining business structure. |
| SD Biosensor | Jan-23 | SD Biosensor, in partnership with SJL Partners, completed the acquisition of Meridian Bioscience, which subsequently ceased trading on NASDAQ. The acquired entity continues operations under new ownership, strengthening SD Biosensor’s position in molecular and infectious disease diagnostics. |
| Abbott | 2023 | Abbott expanded its molecular gastrointestinal testing capabilities, strengthening its infectious disease diagnostics portfolio. This development enhances its position in enteric disease testing through improved molecular assay coverage and broader clinical application reach. |
| Bio-Rad | Jun-21 | Bio-Rad partnered with Seegene to co-develop multiplex molecular diagnostic tests for use on its CFX96 Dx Real-Time PCR System. The collaboration enhances Bio-Rad’s syndromic testing capabilities and expands its molecular diagnostics portfolio for enteric disease applications. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Enteric Disease Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Test Type | Molecular Tests, Immunoassays, Culture-Based Tests, Microscopy-Based Tests, Multiplex Panels |
| Sample Type | Stool, Rectal Swab, Blood, Vomitus |
| End-user | Hospitals & Clinics, Diagnostic Laboratories, Public Health Laboratories, Research & Academic Institutes |
Enteric Disease Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Disease Burden and Diagnostic Gap Assessment |
|
| Public Health Screening Opportunity Analysis |
|
| Point-of-Care Adoption Strategy |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of enteric disease testing?
How is the enteric disease testing industry projected to perform over the next decade?
How is the adoption of molecular diagnostics reshaping testing workflows in the enteric disease testing market?
What impact are government-led screening programs having on enteric disease testing demand?
Why is bacterial disease testing the largest segment in the enteric disease testing market?
Why is parasitic disease testing the fastest-growing segment in the enteric disease testing market?
Why is North America the largest regional market for enteric disease testing?
What is driving enteric disease testing market growth in Asia Pacific?
Which organizations are considered leaders in the enteric disease testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization